Clinical trials in Warsaw – page 138

1 804 clinical trials in Warsaw, Poland across 33 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Warsaw at a glance

1 804

clinical trials

Research sites33

Quick filters

1 804 trials in Warsaw

Open in trial search

Colorectal cancer metastatic

Not recruiting

Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy

Registered drugNo placebo

Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Adagrasib
Sponsor:Mirati Therapeutics Inc.

Contact Research Centre

Pleural mesothelioma

Not recruiting

Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma

Registered drugNo placebo

Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

HIV infection

Not recruiting

Study on the Effects of GSK3739937 for Adults with HIV-1 Who Have Not Yet Received Treatment

Investigational

Study on the Effects of GSK3739937 for Adults with HIV-1 Who Have Not Yet Received Treatment

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Gsk3739937
Sponsor:Viiv Healthcare UK Limited

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo

Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Bristol Myers Squibb International Corporation

Contact Research Centre

Endometrial cancer

Not recruiting

Study Comparing Pembrolizumab and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo

Study Comparing Pembrolizumab and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Bladder cancer

Not recruiting

Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo

Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab, Trastuzumab, and Chemotherapy for Patients with HER2 Positive Advanced Stomach or Gastroesophageal Junction Cancer

Registered drug

Study of Pembrolizumab, Trastuzumab, and Chemotherapy for Patients with HER2 Positive Advanced Stomach or Gastroesophageal Junction Cancer

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Multiple sclerosis+2

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo

Poland

Participants:18–64 years
Substances:Methylprednisolone
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Type 1 diabetes mellitus

Not recruiting

Study on Frexalimab for Preserving Insulin Production in Newly Diagnosed Type 1 Diabetes Patients Aged 12-21 on Insulin Therapy

Registered drug

Study on Frexalimab for Preserving Insulin Production in Newly Diagnosed Type 1 Diabetes Patients Aged 12-21 on Insulin Therapy

Registered drug

Poland

Participants:0–17 years · 18–64 years
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Hypoparathyroidism

Not recruiting

Study on the Effectiveness and Safety of Eneboparatide, Calcitriol, and Calcium Carbonate for Patients with Chronic Hypoparathyroidism

Registered drug

Study on the Effectiveness and Safety of Eneboparatide, Calcitriol, and Calcium Carbonate for Patients with Chronic Hypoparathyroidism

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Alfacalcidol
Sponsor:Alexion Pharmaceuticals Inc.

Contact Research Centre

Mantle cell lymphoma

Not recruiting

Study of Acalabrutinib, Venetoclax, and Rituximab for Patients with Newly Diagnosed Mantle Cell Lymphoma

Registered drugNo placebo

Study of Acalabrutinib, Venetoclax, and Rituximab for Patients with Newly Diagnosed Mantle Cell Lymphoma

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:AstraZeneca AB

Contact Research Centre

Colitis ulcerative

Not recruiting

Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis

Investigational

Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis

Investigational

Poland

Participants:0–17 years · 18–64 years · 65+ years
Substances:Upadacitinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Warsaw

What the registry says about research in the country

01 Respiratory Disease Research

Innovative trials focusing on respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) prevention in older adults. Studies include evaluation of novel vaccine formulations and immune responses in various age groups.

RSV Prevention Studies
Influenza Vaccine Research
Respiratory Infection Management

Particular emphasis on vaccine development for adults aged 60 and older.

02 Immunology Studies

Comprehensive research on meningococcal vaccines across different age groups, from infants to toddlers. Studies evaluate safety profiles and immune responses to various vaccine formulations.

Pediatric Vaccine Development
Immunogenicity Assessment
Vaccine Safety Monitoring

Focus on preventive healthcare through advanced vaccination strategies.

03 Dermatology Research

Studies investigating treatments for psoriasis and psoriatic arthritis, including novel biological therapies and their mechanisms of action.

Plaque Psoriasis Treatment
Biomarker Analysis
Combined Therapy Approaches

Emphasis on moderate to severe cases requiring advanced therapeutic interventions.

04 Oncology Studies

Clinical research focusing on bladder cancer and innovative combination therapies. Studies evaluate treatment efficacy in early-stage non-muscle invasive cases.

Immunotherapy Research
Cancer Treatment Combinations
Disease-Free Survival Analysis

Integration of targeted therapies with standard treatments.

Back to Poland All countries